DeCure for Ehlers-Danlos syndrome, classic-like, 2
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Ehlers-Danlos syndrome, classic-like, 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEhlers-Danlos syndrome, classic-like, 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ehlers-danlos syndrome, classic-like, 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Surgery · 1982 · 62 citations
Vascular Manifestations in Patients With Ehlers-Danlos Syndrome
AbstractEhlers-Danlos syndrome (EDS) is clinically and genetically a heterogenous disorder of connective tissue synthesis. Seven clinical types of this disease have been identified and the underlying biochemical defects defined in types IV through VII. Unfortunately, most patients with major vascular complications of EDS have few, if any of the commonly recognized musculoskeletal and cutaneous abnormalities. Recognition of the correct diagnosis and the application of accepted vascular surgical techniques may improve the morbidity and mortality for these patients.
Journal of Health Statistics Reports · 2025 · 0 citations · open access
The Importance of Early Diagnosis of Ehlers-Danlos Syndrome – A Case Study and Public Health Perspective
AbstractEhlers-Danlos Syndrome (EDS) is a rare, inherited connective tissue disorder, frequently diagnosed with significant delay due to fragmented care and lack of coordination among specialists. We present the case of a 35-year-old woman whose EDS diagnosis was established 17 years after the onset of symptoms. Despite numerous specialist consultations, the focus on isolated symptoms without a holistic approach led to prolonged diagnostic neglect. This case highlights the crucial role of the family physician as a care coordinator, integrating clinical data from various fields and adopting a holistic view of the patient. Early detection of rare diseases such as EDS is vital for public health—it shortens the time to diagnosis, improves patient quality of life, and optimizes healthcare resource utilization. Our analysis underscores the urgent need for systemic solutions: better care coordination, development of integrated medical data tools, and enhanced education of physicians in rare diseases, especially at the primary care level.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
